RedHill Biopharma (RDHL) Tops Q1 Loss Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
RedHill Biopharma Reports 2016 Second Quarter Financial Results
July 26, 2016 7:01 AM EDTRedHill maintains a strong and debt-free balance sheet with $47.7 million in cash at the end of the second quarter, allowing the Company to continue to diligently execute its three ongoing Phase III gastrointestinal disease programs in the U.S. as well as additional clinical programsRecent key milestones include: First patients dosed in the Phase II study with BEKINDA for diarrhea-predominant irritable bowel syndrome (IBS-D)Positive Type B meeting with the FDA supporting the planned confirmatory Phase III study with RHB-105 for H.... More
